瑞舒伐他汀对急性冠脉综合征合并心律失常患者炎性因子的影响  

Impact of Rosuvastatin Calcium therapy to the inflammatory factors change in patients with acute coronary syndrome combined arrhythmia

作　　者：王锐[1] 丁良才[2] 盛柯杰 陈晨[1] 

机构地区：[1]解放军第102医院内科,江苏常州213003 [2]常州市第一人民医院急诊科,江苏常州213003

出　　处：《江苏大学学报（医学版）》2014年第1期68-71,共4页Journal of Jiangsu University：Medicine Edition

摘　　要：目的:探讨急性冠状动脉综合征(ACS)合并心律失常患者应用瑞舒伐他汀治疗后炎性因子的变化。方法:90例ACS合并心律失常的住院患者,按照ACS类型分为不稳定性心绞痛组46例(UA组)、非ST段抬高心肌梗死组13例(USTEMI组)和ST段抬高心肌梗死组31例(STEMI组)。每组患者入院当日均在常规治疗的基础上加用瑞舒伐他汀治疗,检测每组患者治疗前及治疗后2周的血清高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)及白细胞介素-18(IL-18)并进行对比分析。结果:3组患者治疗前血清hs-CRP、TNF-α及IL-18水平存在明显差异(P<0.01),在接受瑞舒伐他汀治疗2周后血清hs-CRP、TNF-α及IL-18均明显降低,差异有统计学意义(P<0.01),且3组患者治疗后各炎性因子间差异无统计学意义(P>0.05)。结论:瑞舒伐他汀可明显降低ACS合并心律失常患者血清hs-CRP、TNF-α及IL-18的水平。Objective： To investigate the effect of Rosuvastatin Calcium treatment to inflammatory factors change in patients with acute coronary syndrome （ACS） combined arrhythmia application. Methods： Ninety cases of ACS combined arrhythmia patients in our hospital were divided into three groups,46 cases of unstable angina group（ group UA） , 13 cases of non ST-segment elevation myocardial infarction group（ group USTEMI） and 31 cases of ST-elevation myocardial infarction group（ group STEMI）. Each group of patients on the basis of routine treatment added by a two weeks treatment of Rosuvastatin Calcium, the patients in each group before and after treatment had their serum hs-CRP, TNF-α and IL-18 were analyzed. Results： The serum hs-CRP, TNF-α and IL-18 content were obviously different among the three groups. After Rosuvastatin Calcium therapy, the serum hs-CRP, TNF-α and IL-18 content of three groups were markedly reduced, compared with before treatment, the differences were statistically significant （P 〈0.01 ）, and they had no significant differences among the three groups （ P 〉 0.05）. Conclusion ： Rosuvastatin Calcium may obviously reduce the serum hs-CRP, TNF-α and IL-18 content of the patients with ACS combined arrhythmia.

关 键 词：急性冠状动脉综合征 瑞舒伐他汀 炎性因子 心律失常 

分 类 号：R541.4[医药卫生—心血管疾病]